Case Report

Anti N-methyl-D-aspartate receptor (NMDAr) encephalitis during pregnancy: A case report

Fedele Dono a,b,d,⇑, Giacomo Evangelista a,d, Stefano Consoli a,d, Giovanna Scorrano c,d, Mirella Russo a,d, Martina di Pietro a, Marco Onofrj a,b, Stefano L. Sensi a,b, Francesca Anzellotti d

a Department of Neuroscience, Imaging and Clinical Science, “G. d’Annunzio” University of Chieti-Pescara, Italy
b Center of Advance Studies and Technologies (CAST), “G. d’Annunzio” University of Chieti-Pescara, Italy
c Department of Pediatrics, “G. d’Annunzio” University of Chieti-Pescara, Italy
d Epilepsy Center, “SS Annunziata” Hospital, Chieti, Italy

Article info

Article history:
Received 13 November 2021
Revised 30 December 2021
Accepted 13 March 2022
Available online 19 March 2022

Keywords:
Maternal outcome
Fetal outcome
Epilepsy
Seizures
Lacosamide

Abstract

Anti-N-methyl-D-aspartate receptor (NMDAr) antibody encephalitis is an autoimmune disorder characterized by reduced synaptic activity of the NMDAr due to circulating antibodies that target the NR1 subunit. Few cases of anti-NMDAR encephalitis during pregnancy have been described. The permeation of anti-NR1 antibodies through the placenta can be instrumental in the development of complications in newborns. We describe a case of a young woman suffering from anti-NMDAR encephalitis during the first trimester of pregnancy and focus on diagnostic and therapeutic management.

© 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

The anti-N-methyl-D-aspartate receptor (NMDAr) antibodies encephalitis is the most frequent autoimmune encephalitis (AE) occurring in young women [1]. This condition is frequently associated with neoplasia, paraneoplastic syndromes, and especially with ovarian teratoma [2]. The autoimmune etiology is characterized by synaptic NMDAr dysfunction driven by antibodies targeting the receptor NR1 subunit [3].

Few cases of anti-NMDAR encephalitis during pregnancy have been described [5]. The permeation of anti-NR1 antibodies through the placenta as well as the mother symptoms may be crucial for the development of complications in newborns [6]. In treating this condition, the clinician must consider the teratogenic and toxic effects of treatments on the fetus and balance them with benefits for the mother. Especially in the first trimester of pregnancy, the use of anti-seizure medication (i.e. carbamazepine and phenytoin), immunomodulatory drugs (i.e., cyclophosphamide), or the radiological assessment of any underlying neoplasia (i.e., computerized tomography of the abdomen and pelvis with contrast enhancement for ovarian teratoma) are associated with increased rates of congenital malformations (like spina bifida and cardiac anomalies) or newborn distress [7].

In the present report, we describe the case of a young woman suffering from anti-NMDAR encephalitis during the first trimester of pregnancy. We aim to highlight the positive maternal and fetal outcome and focus on diagnostic and therapeutic management.

2. Case presentation

A 29-year-old woman in the 7th gestational week came to our observation for the sudden onset of continuous, ongoing, focal motor seizures involving the right side of the face. According to her past medical history, in the previous seven days, the patient had presented several episodes of emotional liability with sudden changes in her mood and behavior (i.e., uncontrolled lapses of crying or laughing). The medical history was negative for any significant comorbidity.

At admission to the Emergency Room, during the neurological evaluation, the patient showed continuous (lasting > 60 min), stereotyped, rhythmic muscle jerks involving the right labial commissure and sialorrhea. The patient was fully aware and did not show other focal neurological signs. The patient underwent a video-electroencephalogram (video-EEG) recording, which showed...
continuous high-amplitude rhythmic 3–5 Hz slow waves and sporadic biphasic sharp waves over the left fronto-centro-temporal derivations (Fig. 1). A diagnosis of focal motor status epilepticus was made according to the International League Against Epilepsy diagnostic criteria [8]. The patient was treated with two boluses of intravenous (IV) lorazepam (4 mg) followed by an IV bolus of levetiracetam (1000 mg) that produced a good electroclinical response. An anti-seizure medication (ASM) course with levetiracetam (1000 mg twice a day) was then started. Soon after, magnetic resonance imaging (MRI) of the brain without contrast and a magnetic resonance angiography (MRA) of the intracranial vessels were performed and revealed no abnormalities. The patient also underwent an obstetric evaluation with ultrasound fetal echography that was negative.

In the following 72 hours, a worsening of the clinical picture was observed. In particular, there was an increased frequency of the aforementioned focal motor seizures, with some episodes eventually evolving in focal-to-bilateral tonic-clonic seizures. The patient also presented psychomotor agitation with non-finalistic movements, aggression, and mutism. The patient was monitored with continuous EEG, which showed continuous high-amplitude rhythmic 3–5 Hz slow waves and sporadic diphasic sharp waves over the left fronto-centro-temporal derivations. Additional brain MRI scans were performed, which now showed hyperintense alterations over the left temporo-fronto-parietal cortex in fluid-attenuated inversion recovery T2-weighted sequences (Fig. 2). No pathological findings were detected in the brain MRA of intracranial vessels. A CT scan of the brain was also performed to exclude subarachnoid hemorrhage, which resulted negative. The CT scan was performed using a lead cover over the abdomen to reduce fetal exposure to radiation. A lumbar puncture was then performed, which showed mild lymphocytic pleocytosis (white blood cells: 8 cells/mm³) with increased protein (70.5 mg/dl) and normal glucose levels. A polymerase chain reaction assessment of neurotropic viruses and the search of oligoclonal bands were negative. However, the antibodies panel for AE revealed high levels of anti-NMDAR antibodies in the cerebrospinal fluid, a finding confirmed in the serum (Table 1). A diagnosis of anti-NMDAr AE was made in line with the Grauss criteria [9]. ASM therapy was implemented with lacosamide (100 mg twice a day) to avoid relapses of bilateral tonic-clonic seizures. In contrast, for the underlying encephalitis, an immunomodulant course with high-dose steroid (prednisone 1 g per 5 days followed by oral prednisolone 60 mg/day for 10 days) and subsequent plasmapheresis (PLEX) therapy (5 cycles in 10 days) were performed. This combined treatment produced a progressive improvement of the clinical picture. The patient also underwent pelvic and abdomen MRI, ovarian echography, and chest-RX, all results were negative. Blood tests (i.e., white and red blood cell counts, white blood cells formula and serum electrolytes) were also negative.

At the 12th gestational week, the fetal ultrasound showed standard biparietal and cerebellar indices, normal abdomen dimension, and heart kinetic. The patient underwent neuropsychological evaluations revealing the presence of attention and language deficits (decreased fluency, palilalia and echolalia), with normal global cognition.

During the following weeks of pregnancy, the patient did not experience any relapse of the neurological and psychiatric manifestations. At the 39th week of gestational age, natural delivery was performed. At the delivery, the newborn presented normal birth weight (2.800 kg) with APGAR 9–10 at the first and the fifth minute. The newborn did not present any sign of fetal distress with no major or minor malformations. The patient decided to avoid breastfeeding. At the follow-up visit, performed 3 months later, the patients did not show abnormalities at the neurological examination. An MRI scan with contrast of the brain indicated complete resolution of the neuroradiological anomalies. The EEG was also unremarkable. At the new neuropsychological evaluations, only
attention deficits with normal global cognition were observed. The patients started a slow down-titration of the ASM therapy with the aim to stop the treatment in the following 3 months. In addition, a follow-up total-body CT scan with contrast, pelvic ultrasonography and breast RX were performed, all negative.

3. Discussion

Anti-NMDAR encephalitis is one of the most frequent autoimmune epilepsies (AE) during pregnancy [10]. According to the literature, the anti-NR1 antibodies can transfer from the mother to the fetus starting at the 13th week of gestation and increasing during the third trimester. Experimental models show that maternal-fetal autoantibodies transfer can cause harmful consequences on the fetus. In previous reports, placental antibodies transfer has been confirmed in a few cases (Table 2). The presence of anti-NR1 antibodies in the newborn was not always associated with detectable neurological deficits, which perhaps are the result of a combination of factors that may include the potential pathogenic effects of the antibodies (usually transient) along with the side effects of sedatives, ASM, and other drugs used for the treatment of AE. In our report we did not test anti-NR1 antibodies serum titer in the newborn due to the absence of any clinical manifestations after the delivery as well as in the following weeks.

The diagnostic and therapeutic management of anti-NMDAR encephalitis during pregnancy is particularly challenging due to the possible fetal side effects of diagnostic and therapeutic interventions. The diagnosis of AE is clinical [4], but instrumental investigations like radiological imaging is supportive and important for a correct differential diagnosis. Some concerns have been raised about using radiation-based techniques (i.e., x-ray procedures and CT scans with or without iodinated contrast) for their potential teratogenic effects whereas the use of MRI scans or
ultrasonography has not been associated with an increased risk of fetal malformation. However fetal safety has been questioned if MRI scan is performed during the first trimester of pregnancy. According to the latest evidence, exposure to MRI during the first trimester of pregnancy is not associated with an increased risk of harm to the fetus or in early childhood. On the other hand, gadolinium MRI at any time during pregnancy can have teratogenic effects and is associated with an increased risk of a broad set of rheumatological or inflammatory newborn complications as well as stillbirth or neonatal death [11]. In considering available data and the risk of teratogenicity, the American College of Radiology concludes that no special consideration is recommended for the first (versus any other) trimester in pregnancy [12]. In our case, the diagnosis of AE and the search of underlying neoplasia were performed by MRI scans and radiation techniques without contrast and employing a low-exposure radiation approach. In addition, the use of a lead cover over the abdomen helped prevent fetal exposure to radiation during CT scans, even though the quantity of radiation was further below the dangerous exposure level. A total-body CT scan with iodinated contrast and pelvic ultrasonography was performed after delivery to exclude the presence of neoplasms.

Around 55% of women suffering from AE have an ovarian teratoma, but other tumors and hematological diseases have also been described. As reported in Table 2, several cases of AE during pregnancy associated with ovarian teratoma have been described. However, our report stresses that AE onset during pregnancy is not necessarily associated with underlying tumor pathology, though screening for neoplasms is essential. The range and frequency of associated malignancies differ according to the autoantibody detected. The early detection of tumors is important for the prognosis but is also critical as immunotherapy could hamper tumor detection. If the first neoplastic screening is negative, further assessment should be repeated every 4-6 months for 2 years [13]. However, the recommendation should be personalized according to risk factors, clinical evolution, and medical resources.

Concerning therapy, it is well known that some ASMs and immunomodulatory treatments can have teratogenic and toxic effects. Evidence indicates that certain ASMs, especially first-generation drugs (phenytoin or phenobarbital) are associated with increased rates of congenital malformations (spina bifida, cardiac anomalies) as well as with newborn distress [7]. In contrast, new-generation ASMs seem to exhibit a safer profile [14]. The risk of major congenital malformations has been confirmed for valproic acid [14], whereas no consistent association with major congenital malformation has been indicated for lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, gabapentin, and lacosamide [15]. Fetal valproate exposure poses a dose-dependent risk for malformations that exceeds other antiseizure medications. Teratogens act in a dose-dependent manner and some studies suggest that even some of our apparently safer ASM in regard to malformations appear to have dose-dependent risks [14,16].

Even though seizures in AE are characteristically resistant to ASMs, these drugs maintain a role for symptomatic management. A recent study [17] tried to evaluate seizure responses to immunotherapy and ASM in patients with AE. Interestingly, ASM treatment (even after changing dosage or treatment regimen) was associated with low seizure control and, in some patients, the use of ASM was followed by serious psychiatric manifestations (i.e. behavioral changes, psychosis and suicidal thoughts). On the other hand, patients treated with immunotherapy resulted in seizure freedom faster (28 days from the start of the treatment) than ASM (59 days from the start of the treatment) and also more often (53% of patients) than ASM (14% of patients). Patients treated earlier in the disease course with immunotherapy were seizure-free quicker. Thus, ASM should be considered as an add-on treatment to immunotherapy in order to better achieve seizure freedom. Furthermore, a recent retrospective study demonstrated a considerably higher efficacy of sodium channel blocking compounds to produce seizure freedom in AE patients. In our case, we administered ASM (in particular the sodium channel blocker lacosamide) to prevent the onset of focal-to-bilateral tonic-clonic seizures, a condition that could have been detrimental to fetal well-being. After the delivery, in line with the aforementioned evidence, we aimed to stop ASM in the following 3 months.

Immunomodulatory treatment with systemic corticosteroids seems to be safe during pregnancy. Indeed, pregnant women receiving corticosteroids usually show a low risk of developing major congenital malformations, even though premature rupture of amniotic membranes and low birth weight babies may occur [18]. Some authors indicated an increased risk of preterm birth, small for gestational age, low birth weight, intrauterine growth restriction and neonatal intensive care unit admission [18]. Reports describing the use of PLEX during pregnancy are limited. However, consensus reports suggest that PLEX is safe and appropriate, especially in patients who have failed other immunomodulatory treatments. PLEX can be used safely during pregnancy with the proper training of a multidisciplinary team. Intravenous immunoglobulins (IVIg) are also safe during pregnancy. The obstetric literature contains numerous reports of intravenous immunoglobulin therapy for various conditions encountered during pregnancy [19]. Furthermore, several case reports and case series (Table 2) showed a favorable outcome in pregnancy patients with AE treated with IVIg with a low occurrence of side effects as well as infectious morbidity. On the other hand, the use of the chimeric anti-CD20 monoclonal antibody rituximab as third-line immunomodulatory treatment in non-responder AE during pregnancy is controversial. Rituximab is a pregnancy category C medication and should be stopped 12 months prior to attempting conception. Even though anecdotal cases are reported in the literature [20], safety and efficacy data about rituximab in the treatment of AE during pregnancy are not available. A recent study [21] based on a global database

---

**Table 1**

Cerebrospinal fluid (CSF) and serum analysis.

| Cytotoxic examination | Result | Autoimmune panel | Titer |
|----------------------|--------|------------------|------|
| Appearance           | Clear  | Anti-Ca	extsuperscript{2+} Channel Ab | Negative |
| White cells          | 8 cells/mm³ | Anti-VGCCX Ab | Negative |
| Glucose              | 66 mg/dl | Anti-GLUR3 Ab | Negative |
| Proteins             | 70.5 mg/dl | Anti-AMPA1,2 Ab | Negative |

**Microbiological panel**

| Item   | Result | Autoimmune panel | Titer |
|--------|--------|------------------|------|
| HSV-1  | Negative | Anti-LGI1 Ab | Negative |
| HSV-2  | Negative | Anti-NMDAR Ab 1:32 | Negative |
| HHV-6  | Negative | Anti-GABA Ab | Negative |
| HHV-7  | Negative | Anti-GAD65 Ab | Negative |
| HHV-8  | Negative | Anti-MOG Ab | Negative |
| CMV    | Negative | Anti-AQP4 Ab | Negative |
| EBV    | Negative | Oligoclonal bands | Negative |
| VZV    | Negative |  | |

**Serum analysis**

| Autoimmune panel | Titer |
|------------------|------|
| Anti-Ca	extsuperscript{2+} Channel Ab | Negative Anti-Mi1 Ab | Negative |
| Anti-VGCCX Ab     | Negative Anti-Ma2/Ta Ab | Negative |
| Anti-GLUR3 Ab     | Negative Anti-CV2 Ab | Negative |
| Anti-AMPA1,2 Ab   | Negative Anti-Hu Ab | Negative |
| Anti-CASPR2 Ab    | Negative Anti-Ri p54 Ab | Negative |
| Anti-LGI1 Ab      | Negative Anti-Yo Ab | Negative |
| Anti-NMDAR Ab 1:32 | Anti-recoverin Ab | Negative |
| Anti-GABA Ab      | Negative Anti-amphiphysin Ab | Negative |
| Anti-GAD65 Ab     | Negative Anti-SOX1 Ab | Negative |
| ANA               | Negative Anti-Zic4 Ab | Negative |
| ENA               | Negative Anti-titin Ab | Negative |
| Antiphospholipid antibodies | Negative Anti-Ti Ab | Negative |

F. Dono, G. Evangelista, S. Consoli et al. Epilepsy & Behavior Reports 19 (2022) 100535
| Reference          | Age | Gestational age (weeks) | Presenting symptoms                                | Teratoma | Neonatal antibodies | Treatment                                      | Outcome: mother | Outcome: baby                                      |
|--------------------|-----|-------------------------|----------------------------------------------------|----------|---------------------|------------------------------------------------|-----------------|---------------------------------------------------|
| Ito et al. [22]    | 2010 19 | 17                     | Dyskinesia, behavior abnormalities                  | No       | Not tested          | Corticosteroids                                  | Normal          | Emergency C-section at 33 weeks gestation. Normal baby |
| Kumar et al. [23]  | 2010 19 | 17                     | Behavior abnormalities                               | No       | Not tested          | IV Methylprednisolone                             | Normal          | Normal vaginal delivery at 37 weeks gestation. Normal baby |
| Kumar et al. [23]  | 2010 20 | 8                      | Behavior abnormalities                               | No       | Not tested          | IVIg                                             | Minimal deficits | Termination of pregnancy at 10 weeks               |
| Kumar et al. [23]  | 2010 19 | 14                     | Headache followed by behavior abnormalities         | Yes      | Not tested          | IVIg Methylprednisolone Resection of teratoma    | Both mother and baby survived C-section delivery at 38 weeks gestation | Normal           |
| McCarthy et al.    | 2012 32 | 8                      | Autonomic symptoms, behavior abnormalities          | Yes      | No                  | IVIg Methylprednisolone PLEX Resection of teratoma | Normal          | C-section delivery at 32 weeks. Normal baby        |
| Jagota et al.      | 2014 18 | 9                      | Orolingual movements, eye deviation, fever          | No       | Yes                 | Azathioprine IVIg                                 | Patient died due to infection. Baby survived, delivered at 34 weeks (NVD) Baby-Delayed in global development, seizures | Global developmental delay. Seizure. Cortical dysplasia |
| Lamale-Smith et al. | 2015 24 | 20                     | Catatonia, disoriented, confused                     | No       | Yes                 | IV Methylprednisolone IVIg                       | Disinhibition, memory impairment | C-section at 28 weeks. Normal                       |
| Chan et al.        | 2015 23 | 1st semester            | Fever, hallucinations, disinhibited behavior, confusion | Yes      | Not tested          | IVIg Methylprednisolone PLEX Rituximab Resection of teratoma | Normal          | Miscarriage                                        |
| Mathis Stephanie et al. | 2015 21 | 10                     | Behavior abnormalities                               | No       | Not tested          | IV- Methylprednisolone IVIg                     | Slight memory impairment | Normal vaginal delivery at 40 weeks gestation Miscarriage |
| Kim et al.         | 2015 28 | 7                      | Abnormal behavior, hypoventilation, dyskinesia and epileptic seizure | Yes      | Not tested          | IV- Methylprednisolone IVIg Oral corticosteroids PLEX, RTX, Resection of teratoma | Slight cognitive function deficits | Miscarriage                                        |
| Xiao et al. [30]   | 2017 24 | 28                     | Psychiatric symptoms – visual and auditory hallucinations | No       | Not tested          | IVIg IV- Methylprednisolone Bilateral ovarian wedge resection Oral corticosteroids IV- Methylprednisolone, PLEX | Normal          | Emergency C-section at 33 weeks gestation. Normal baby |
| Shanani et al.     | 2015 26 | 22                     | Headache, behavioral abnormalities                   | No       | Not tested          | IVig, RTX, cyclophosphamide, Resection of teratoma | Poor responder  | C-section. Normal baby                             |
| Joubert et al.     | 2020 19 | 25                     | Visual hallucination, delirium and agitation        | Yes      | Not tested          | IVIg, cyclophosphamide                           | Poor responder  | C-section. Normal baby                             |
| Joubert et al.     | 2020 37 | 33                     | Bulbar palsy and hemifacial sensitivity deficit     | No       | Not tested          | IVIg, cyclophosphamide                           | Normal          | C-section. Normal baby                             |
| Joubert et Al.     | 2020 31 | 20                     | Orofacial dyskinesia, cognitive fluctuation, memory deficits, delirium | Yes      | Not tested          | IVIg, RTX, cyclophosphamide, Resection of teratoma | Poor responder  | C-section. Normal baby                             |
| Joubert et al.     | 2020 25 | 5                      | Epilepsy and behavior abnormalities                 | No       | Not tested          | IVIg, PLEX, RTX                                  | Poor responder  | Prematurity                                        |

(continued on next page)
encountering 231 pregnant women treated with rituximab showed that of 153 pregnancies with known outcomes, 90 resulted in live births. However, the study reported 22 infants born prematurely, 11 neonates with hematologic abnormalities and 4 neonatal with systemic infections. In addition, 2 congenital malformations (i.e.: clubfoot in one twin, and cardiac malformation in a singleton birth) were identified.

In our case, the treatment with steroids and PLEX produced complete relief of the symptoms, good clinical response, and no evidence of newborn’s malformation. In line with previous reports (Table 2), treatment with steroids and PLEX has been associated with a good clinical outcome for the newborn and mother. In addition, the follow-up evaluation showed sustained benefits with full remission of the neuropsychological deficits.

4. Conclusion

Our case describes the diagnostic and therapeutic management of a patient suffering from anti-NMDAR encephalitis during pregnancy. Immunomodulatory treatments along with ASM have played a key role in control of focal-to-bilateral seizures. The prompt diagnosis and the adequate treatment led to a complete recovery of the mother and a good newborn outcome.

5. Statement of ethics

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. The paper is exempt from ethical committee approval because it is not necessary to publish the case report.

Data availability statement

The data are available from the corresponding author upon reasonable request.

Conflict of interest statement

The authors declare no conflict of interest.

References

[1] Liu C-Y, Zhu J, Zheng X-Y, Ma C, Wang X. Anti-N-methyl-D-aspartate receptor encephalitis: A severe, potentially reversible autoimmune encephalitis. Mediators Inflamm 2017;2017:6361479. https://doi.org/10.1155/2017/6361479. Epub 2017 Jun 18. PMID: 28698711; PMCID: PMC5494059.

[2] Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61(1):25–36. https://doi.org/10.1002/ana.20105. PMID: 17262855; PMCID: PMC2430743.

[3] Wenke NK, Kreye J, Andrzejek E, Casteren A, Leuhner J, Murgueto MS, et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann Neurol 2019;86(5):771–6. https://doi.org/10.1002/ana.25451. Epub 2019 Apr 2. PMID: 30843274; PMCID: PMC6593665.

[4] Huang Q, Xie Y, Hu Z, Tang X. Anti-N-methyl-D-aspartate receptor encephalitis: A review of pathogenic mechanisms, treatment, prognosis. Brain Res 2020;1727:146549. https://doi.org/10.1016/j.brainres.2019.146549. Epub 2019 Nov 11. PMID: 31726044.

[5] Kim J, Park SH, Jung YR, Park SW, Jung DS. Anti-NMDA Receptor Encephalitis in a Pregnant Woman. J Epilepsy Res 2015 Jun 30;5(1):29–32. https://doi.org/10.14581/jer.15008. PMID: 26157673; PMCID: PMC4494994.

[6] Hilderink M, Titulaer MJ, Schreurs MW, Keizer K, Bunt JE. Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmission. Neurrol Neuroimunonul Neuroinflamm 2015;2(4): -. https://doi.org/10.1212/NNI.0000000000000126. PMID: 26140282; PMCID: PMC4476049.

[7] Narayan B, Nelson-Piercy C. Medical problems in pregnancy. Clin Med (Lond) 2017;17(3):251–7. https://doi.org/10.7861/dimmedicine.17-3-251. PMID: 28572227; PMCID: PMC5297557.

[8] Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. The definition and classification of status epilepticus–Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015 Oct;56(10):1515–23. https://doi.org/10.1111/epi.13121. Epub 2015 Sep 4 PMID: 26336950.

[9] Graus F, Delattre JY, Antoine JC, Dalmau J, Gironeto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004;75(8):1135–40. https://doi.org/10.1136/jnnp.2003.034447. PMID: 15258215; PMCID: PMC1739186.

[10] Al-Diwani A, Handel A, Townsed L, Pollak T, Leite MI, Harrison PJ, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019;6(3):235–46.

[11] Ray JC, Vermeulen MJ, Bharatha A, Montanera WJ, Park AL. Association between MRI exposure during pregnancy and fetal and childhood outcomes. Jama 2016;316(9):932–61. https://doi.org/10.1001/jama.2016.12125. Epub 2016 Dec 29. PMID: 27599330.

[12] Kanal E, Barkovich AJ, Bell C, Borgstedt JP, Bradley WG, Froelich JW, et al. ACR guidance document on MR safe practices: 2013. J Magn Reson Imaging
[13] Ropper AH, Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378(9):840–51. https://doi.org/10.1056/NEJMra1708712 PMCID: 2949018.

[14] Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018;17(6):530–8. https://doi.org/10.1016/S1474-4422(18)30107-8. Epub 2018 Apr 18. PMID: 29680205.

[15] Blotière P-O, Raguideau F, Weill A, Elefant E, Perthus I, Goulet V, et al. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 2019;93(2):e167–80. https://doi.org/10.1212/WNL.0000000000007696. Epub 2019 Jun 12. PMID: 31189695; PMCID: PMC6656651.

[16] Meador K. Teratogenicity and antiseizure medications. Epilepsy Curr 2020;20(6_suppl):15S–7S. https://doi.org/10.1177/1535759720945298.

[17] de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABA B R encephalitis. Neurology 2019;92(19):e2185–96. https://doi.org/10.1212/WNL.0000000000007475. Epub 2019 Apr 12. PMID: 30979857; PMCID: PMC6537134.

[18] Clark AL. Clinical uses of intravenous immunoglobulin in pregnancy. Clin Obstet Gynecol 1999;42(2):368–80. https://doi.org/10.1097/00003081-199906000-00021. PMID: 10370855.

[19] Joubert B, García-Serra A, Planagumà J, Martínez-Hernandez E, Kraft A, Palm F, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117(5):1499–506. https://doi.org/10.1182/blood-2010-07-295444. Epub 2010 Nov 23 PMID: 21098742.

[20] Keskin AO, Tanburuglu A, Idman E, Ozturk V. Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: a case report. J Obstet Gynecol Res 2019;45:935–7.

[21] Jung KO, Moon HJ. A case of NMDAR encephalitis treated in the third trimester - novel arterial spin labeling findings and a review of literature. J Neuroimmunol 2020;315:833–43. https://doi.org/10.1016/j.jneuroim.2020.377235. Epub 2020 Apr 6. PMID: 32279021577235.

[22] Tailland M, Le Verger L, Honnorat J, Biquard F, Codron P, Cassereau J. Post-herpetic anti-N-methyl-d-aspartate receptor encephalitis in a pregnant woman. Revue Neurologique 2020;176(1-2):129–31. https://doi.org/10.1016/j.neuro.2019.01.402. Epub 2019 Sep 18. PMID: 31542179.